Compare Davita Inc (DVA) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Williams-Sonoma, Inc. — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Williams-Sonoma, Inc. trades at $216.47 (market cap $25.51B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.4% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | WSM | |
|---|---|---|
Market Cap | $14.92B | $25.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $240.06 |
52-Week Low | $103.87 | $163.62 |
Enterprise Value | $27.47B | $26.35B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Williams-Sonoma (WSM) trades at $216.65, down 2.3% on the day, with a bullish technical outlook supported by moving averages but mixed oscillators. The company demonstrates strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has declined slightly from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten estimates, and the company maintains active brand collaborations and dividend payments.
The stock presents a balanced outlook with solid fundamentals and analyst consensus near the current price, but faces risks from revenue volatility and competitive pressures. Upside potential exists if earnings momentum continues, while macroeconomic headwinds and retail sector challenges pose downside risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
